
Hagop Kantarjian/mdanderson.org
Apr 18, 2025, 18:37
Hagop Kantarjian: Historical development, current status, and future research of olverembatinib
Hagop Kantarjian, Associate Vice President for Global Academic Programs at MD Anderson Cancer Center, shared on X a recent paper published in ACS Journals:
“Historical development, current status, and future research of olverembatinib, a new third-generation BCR::ABL1 TKI with significant activity and favorable safety profile.”
Authors: Hagop Kantarjian et al.
See more posts by Hagop Kantarjian on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 19, 2025, 13:05